Is CorMedix, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for CorMedix, Inc. has moved from attractive to very attractive. The company appears to be undervalued, particularly when considering its PEG ratio of 0.42, which suggests strong growth potential relative to its price, alongside a P/E ratio of 55 and an EV to EBITDA of 57.92. In comparison, Xeris Biopharma Holdings, Inc. has a P/E of -38.70, indicating significant challenges, while CorMedix's metrics reflect a more favorable valuation profile.
Despite recent underperformance with a 1-week return of -5.13% compared to the S&P 500's 1.70%, CorMedix has shown resilience with a year-to-date return of 25.68%, outpacing the S&P 500's 13.30%. This performance, combined with its strong return on capital employed (ROCE) of 38.54% and return on equity (ROE) of 14.95%, reinforces the attractiveness of the stock as a long-term investment opportunity.